DOV-102677 is a psychoactive drug being developed by Merck and is currently in clinical trials. It is a triple reuptake inhibitor, or serotonin-norepinephrine-dopamine reuptake inhibitor. It is the-enantiomer of DOV-216,303, and its-enantiomer is DOV-21,947.